Ys Pharma launches Kadason medicated shampoo in the U.S.

Ys Pharma Inc. has launched Kadason, an OTC medicated shampoo for seborrheic dermatitis, and is selling it direct to U.S. consumers through ys-ph.com. The product uses 1.80% salicylic acid and enters a market where many shampoos target dandruff but not the recurring scalp condition specifically.

Why it matters: - Seborrheic dermatitis is a chronic, relapsing scalp condition that often returns even after symptoms ease. - The condition affects an estimated 5.86% of the U.S. population, based on a 2024 systematic review and meta-analysis published in JAMA Dermatology. - Kadason is positioned as a shampoo designed specifically for seborrheic dermatitis, not general dandruff.

What happened: - Ys Pharma Inc. announced the U.S. launch of Kadason on Aug. 18, 2026. - Kadason is now available to U.S. consumers through the brand's direct-to-consumer website at ys-ph.com. - The company is selling Kadason as an over-the-counter medicated shampoo.

The details: - Kadason contains 1.80% salicylic acid. - The active ingredient is recognized under the U.S. Food and Drug Administration's OTC Drug Monograph M032 for controlling symptoms of seborrheic dermatitis. - Ys Pharma says regular use helps control flaking, scaling and itching associated with seborrheic dermatitis of the scalp. - The formula is oil-free and silicone-free. - The shampoo also includes Tremella fuciformis extract, aloe vera, green tea extract and dipotassium glycyrrhizate. - Those ingredients are intended to support scalp hydration and comfort during ongoing use. - Kadason was developed in Japan with pharmacists. - The product is manufactured in the United States to U.S. quality and manufacturing standards. - Ys Pharma is headquartered in New York and serves as the official distributor. - The company describes Kadason as a federally regulated OTC scalp care product for seborrheic dermatitis and dandruff. - Kadason is an over-the-counter drug product for external use only. - The product label says to use only as directed and to read the Drug Facts label before use. - The label also says to stop use and consult a doctor if irritation occurs or symptoms persist. - The company advises consulting a dermatologist before use if a person has a severe scalp condition.

Between the lines: - Kadason is entering a niche that sits between cosmetic dandruff shampoos and condition-specific medicated care. - The launch leans on regulatory positioning, domestic manufacturing and a direct-to-consumer model to stand out in a crowded aisle. - The founder's personal experience with seborrheic dermatitis is part of the brand's origin story and signals a product built around recurring-use management.

What's next: - Kadason will likely compete on category specificity, convenience and ongoing-use positioning rather than on one-time symptom relief. - Sales through ys-ph.com give Ys Pharma a direct line to consumers managing a chronic scalp condition. - A subscription option at $27.99 per month suggests the company expects repeat purchases.

The bottom line: - Ys Pharma is betting there is room in the U.S. market for a medicated shampoo made specifically for seborrheic dermatitis, with FDA-monograph ingredients and direct-to-consumer distribution.